International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2808-2814 www.ijprajournal.com ISSN: 2456-4494

ICH Guideline for Pharmacovigilance: A Framework for Global Pharmacovigilance Practice

Prof. (Dr.) Mohd.Wasiullah[1*], Prof.(Dr.) Piyush Yadav[2], Asst. Prof. Mohit vishwakarma[3], Rishi Prasad Jaiswal[4]

Date of Submission: 25-04-2025 Date of Acceptance: 05-05-2025

ABSTRACT
Pharmacovigilance (PV), the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, is a critical component of public health and regulatory science. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has developed comprehensive guidelines to harmonize PV practices globally, ensuring drug safety and efficacy across regions. This abstract provides an overview of the ICH pharmacovigilance framework, its key guidelines, and its role in shaping a global standard for drug safety monitoring.The ICH PV guidelines aim to align regulatory expectations between the United States, Europe, Japan, and other participating regions, thus facilitating a streamlined and coordinated approach to post-marketing surveillance. Key among these guidelines are ICH E2E (Pharmacovigilance Planning), E2D (Post-Approval Safety Data Management), and E2B (Electronic Transmission of Individual Case Safety Reports). These documents provide a structure for industry and regulators to collect, analyze, and communicate safety data in a consistent and transparent manner.The ICH E2E guideline outlines the development of a Pharmacovigilance Plan, which helps sponsors identify and mitigate potential safety risks based on pre- and post-marketing data. E2D offers guidance on collecting and reporting adverse drug reactions, emphasizing the importance of timely and accurate case management. E2B, perhaps the most technically focused guideline, facilitates electronic exchange of safety reports, ensuring standardized data formats for interoperability across global databases like EudraVigilance and the FDA's FAERS.Together, these guidelines promote early detection of safety signals, risk minimization, and informed regulatory decision-making. They also support the creation of Risk Management Plans (RMPs) and Periodic Benefit-Risk Evaluation Reports (PBRERs), which are essential tools for ongoing benefit-risk assessments throughout a product's lifecycle. The harmonized PV framework allows pharmaceutical companies to implement unified strategies for global safety monitoring, reducing duplication of efforts and ensuring compliance with international regulatory standards.

Keywords:ICH Guidelines,Pharmacovigilance , Global pharmacovigilance,Drug safety,Adverse drug reaction (ADR),Risk management

I. INTRODUCTION

Pharmacovigilance (PV) is a critical aspect of healthcare that focuses on monitoring, detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems. The practice ensures that medicines remain safe and effective throughout their lifecycle, from clinical development through post-marketing use. This chapter provides an in-depth understanding of pharmacovigilance, emphasizing its role in drug safety, its importance in public health, and the necessity for a global framework to enhance the effectiveness of pharmacovigilance activities worldwide. Pharmacovigilance is defined by the World Health Organization (WHO) as "the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems." The main goal of pharmacovigilance is to protect patients from the potential harms of medications, ensuring that the benefits of drugs outweigh their risks. As new drugs are developed and brought to market, pharmacovigilance systems play an essential role in continuously monitoring their safety to safeguard public health.

Pharmacovigilance begins as early as the clinical development phase of drugs, where the safety of a drug is carefully monitored in clinical trials. However, clinical trials can only reveal a limited range of potential adverse effects. These trials are typically conducted on a relatively small and specific group of patients under controlled conditions, which may not fully represent the diverse populations that will eventually use the

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2808-2814 www.ijprajournal.com ISSN: 2456-4494

drug. Moreover, the duration of clinical trials is usually limited, meaning some long-term or rare adverse effects may not be identified.

Once a drug is approved and introduced to the market, the real-world data collected through post-marketing surveillance becomes critical for identifying any unforeseen adverse effects or drug-related issues that were not detected during the clinical trials. The importance of this phase cannot be overstated because it is during post-marketing surveillance that the broader population's diverse characteristics, such as comorbidities, polypharmacy, and genetic differences, come into play.The primary aim of pharmacovigilance is to ensure that medicines are used safely and effectively. By identifying ADRs and other drug-related issues in a timely manner, pharmacovigilance can help prevent harm to patients. Through early detection of adverse events, pharmacovigilance systems can alert the public and medical professionals about the potential risks associated with certain drugs, enabling them to make informed decisions regarding treatment options.

Globalization of the Pharmaceutical Market:

In an increasingly globalized world, medicines are distributed and used across borders. This creates both opportunities and challenges for pharmacovigilance systems.

While patients in different regions benefit from the availability of a wide range of medications, the global nature of drug markets means that the safety of these drugs must be monitored on a global scale.Adverse drug reactions and other drug-related problems do not respect national borders. A drug that causes harm in one country can have similar effects elsewhere. Additionally, international trade and travel expose individuals to medicines from different regulatory environments, potentially leading to differences in the safety profile of drugs across regions. For example, a drug that is widely used and approved in one country may be subject to different regulations or monitoring practices in another.This global variability emphasizes the need for an international framework that allows for harmonized pharmacovigilance practices, facilitates the sharing of safety information, and promotes coordinated responses to drug safety concerns. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a key role in promoting global collaboration in pharmacovigilance by providing guidelines that harmonize safety standards and practices across regions.A global framework would help ensure that pharmacovigilance practices are standardized across different regions, facilitating the collection and sharing of safety data.

The sharing of pharmacovigilance data allows for more comprehensive and accurate risk assessments, as data from multiple countries can help identify potential safety signals that may not be evident from a single region. A global framework also ensures that best practices in pharmacovigilance, such as signal detection techniques, risk management strategies, and adverse event reporting systems, can be disseminated and adopted worldwide.

The ICH and its Role in Global Pharmacovigilance

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is one of the most influential bodies in shaping the global landscape of pharmaceutical regulations. Since its inception, ICH has played a critical role in harmonizing regulatory requirements across countries and regions, thereby enhancing the quality, safety, and efficacy of medicines worldwide. This chapter delves into the role of the ICH in global pharmacovigilance, including an overview of the organization, its contribution to global safety standards, and a review of key pharmacovigilance guidelines such as E2E and E2E(R2).The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is a global organization established in 1990 with the aim of improving public health through harmonization of drug regulations across different regions. The council was formed as a response to the growing need for international cooperation to streamline the development and approval processes for pharmaceutical.

The ICH was created by regulatory authorities and pharmaceutical industry representatives from the **European Union (EU)**, **Japan**, and the **United States (US)**. The organization sought to overcome the challenge posed by the differences in regulatory requirements between these major pharmaceutical markets. The purpose was to develop guidelines that would align regulatory standards across these regions, thus facilitating faster and more efficient drug

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2808-2814 www.ijprajournal.com ISSN: 2456-4494

development while maintaining rigorous safety standards.

Today, ICH membership extends beyond the founding regions, with many other countries and regions joining as **Observer** or **Participant** members. Notably, the **World Health Organization (WHO)**, **Canada**, and **Switzerland** are also involved, making the organization a truly global entity. This inclusivity has ensured that ICH guidelines are now adopted widely across various pharmaceutical markets, contributing to the harmonization of drug development practices globally.

ICH's Core Activities

The core activities of ICH are centered on the development of guidelines, which cover a wide array of technical requirements for drug development, registration, and post-market monitoring. These guidelines focus on key aspects of pharmaceutical regulation, including:

- **Quality**: Standards for manufacturing processes and testing.
- **Safety**: Guidelines on evaluating the safety of drugs, including pharmacovigilance practices.
- **Efficacy**: Requirements for assessing the effectiveness of drugs in clinical trials.
- **Multidisciplinary Issues**: Including pharmacovigilance and the management of risks associated with marketed drugs.

The **pharmacovigilance** guidelines developed by ICH are some of the most critical, ensuring that global safety standards are maintained throughout a drug's lifecycle. The adoption of these guidelines by national regulatory authorities has made them a cornerstone in the global effort to protect public health.

ICH's Contribution to Global Safety StandardsHarmonization of Regulatory Standards

One of the primary roles of ICH is to harmonize regulatory requirements across different regions. Before ICH, pharmaceutical companies had to navigate a complex web of regulatory systems, each with its own rules, timelines, and requirements for clinical trials, drug approval, and post-marketing surveillance. This not only led to inefficiencies in drug development but also delayed access to life-saving medications.

By working with regulatory bodies from different regions, ICH has created a common platform for the development of guidelines that ensure regulatory requirements are aligned across the European Union, United States, Japan, and other countries that have since adopted these standards. This harmonization process has significantly reduced the burden on pharmaceutical companies, enabling them to bring drugs to market more quickly while ensuring that safety standards are upheld.For pharmacovigilance, the harmonization efforts by ICH have been instrumental in establishing a global framework for monitoring drug safety. Previously, different regions had varying approaches to adverse drug reaction (ADR) reporting, signal detection, and risk management. The adoption of ICH's pharmacovigilance guidelines, such as E2Eand E2E(R2), has allowed for consistent practices across borders, facilitating the exchange of safety data and improving the ability to respond to emerging safety issues.

- **Adverse Event Reporting**: The E2E guideline emphasizes the importance of collecting adverse event reports during both pre-marketing and post-marketing phases. It recommends the use of consistent terminology, such as the MedDRA (Medical Dictionary for Regulatory Activities), for reporting adverse events to ensure clarity and comparability across different regions.
- **Risk Management**: The guideline introduces a proactive approach to managing drug safety risks. It encourages pharmaceutical companies to assess the risks of drugs continuously and implement risk minimization strategies, such as risk communication or risk-reduction programs.
- **Pharmacovigilance Systems**: The guideline sets out the requirements for developing robust pharmacovigilance systems within pharmaceutical companies. These systems must be capable of collecting, analyzing, and reporting ADRs efficiently and in a timely manner.
- **Data Sharing**: E2E establishes the importance of sharing safety data globally. By promoting the exchange of information between regulatory authorities and stakeholders, it helps ensure a coordinated response to drug safety concerns.

Core Principles of Pharmacovigilance under ICH Guidelines

Pharmacovigilance plays a fundamental role in ensuring the safety and efficacy of pharmaceutical products throughout their lifecycle. The International Council for Harmonisation of

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2808-2814 www.ijprajournal.com ISSN: 2456-4494

Technical Requirements for Pharmaceuticals for Human Use (ICH) has established several critical guidelines to standardize pharmacovigilance practices globally, providing a framework for the collection, reporting, and management of adverse drug reactions (ADRs), the risk management and minimization strategies, and signal detection and data analysis. These core principles not only enhance patient safety but also promote the continuous monitoring of medicines in clinical practice, helping to address emerging safety concerns. This chapter delves into the core principles of pharmacovigilance under ICH guidelines, outlining key processes and practices for ADR collection and reporting, risk management strategies, and signal detection and analysis.

Reporting ADRs under ICH Guidelines

The ICH guidelines **E2E** and **E2E(R2)** emphasize the need for **standardized reporting** systems to collect ADR data. This includes:

- **MedDRA (Medical Dictionary for Regulatory Activities)**: This dictionary is a standardized terminology for coding ADRs. The ICH encourages the use of MedDRA to ensure uniformity in how ADRs are categorized and reported across different regions. MedDRA helps to categorize ADRs by body system and severity, making the data easier to analyze and compare internationally.
- **Adverse Event Reporting Forms**: The ICH recommends the use of standardized reporting forms for ADRs, ensuring that all essential information (such as the description of the event, drug details, patient demographics, and outcomes) is captured. These forms are often submitted to national regulatory agencies and may be shared across global pharmacovigilance systems.
- **Periodic Safety Update Reports (PSURs)**: ICH guidelines require pharmaceutical companies to submit **PSURs** at regular intervals. PSURs provide an overview of the safety profile of a drug, based on collected ADR data, and include information on any newly identified risks or safety concerns.
- **Spontaneous Reporting Systems**: Spontaneous reporting systems are critical for collecting ADR data. Healthcare professionals, patients, and pharmaceutical companies are encouraged to report ADRs voluntarily.

Regulatory Requirements and Compliance in Pharmacovigilance

Pharmacovigilance, the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, is a critical component of ensuring drug safety across the globe. Regulatory bodies worldwide play a central role in enforcing safety measures and guidelines that help monitor, manage, and mitigate the risks associated with pharmaceutical products. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides the framework for harmonizing regulatory practices, but national and international regulatory bodies still hold the responsibility for enforcing pharmacovigilance activities within their respective jurisdictions.In this chapter, we will explore the global regulatory landscape in pharmacovigilance, focusing on key regulatory bodies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). We will also discuss the compliance with ICH guidelines, highlighting how pharmaceutical companies and other stakeholders adhere to global pharmacovigilance standards. Finally, we will examine the requirements for post-marketing surveillance—the ongoing monitoring of drug safety once a product is on the market.

Global Regulatory Landscap&Their Roles in Pharmacovigilance

The regulation of pharmacovigilance is a complex global endeavor involving various national and international regulatory authorities. These agencies ensure that pharmaceutical products are safe, effective, and available to patients while minimizing the risks associated with drug use. The roles of regulatory bodies include overseeing the approval process, implementing pharmacovigilance activities, and ensuring ongoing monitoring and post-marketing surveillance.

U.S. Food and Drug Administration (FDA)

The FDA, an agency of the U.S. Department of Health and Human Services, plays a critical role in pharmacovigilance in the United States. The FDA is responsible for overseeing the safety and effectiveness of drugs, biologics, and medical devices. Its responsibilities in pharmacovigilance are governed primarily by the Federal Food, Drug, and Cosmetic Act and other relevant laws, such as the Food and Drug

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2808-2814 www.ijprajournal.com ISSN: 2456-4494

Administration Amendments Act (FDAAA) of 2007, which introduced significant reforms to post-market drug safety regulations.

- **Adverse Event Reporting**: Under the **FDAAA**, the FDA requires mandatory reporting of adverse events by pharmaceutical companies. Companies must report **serious and unexpected adverse drug reactions (ADRs)** to the FDA within 15 days of receiving information about the event. The FDA manages the **Adverse Event Reporting System (AERS)**, a database for reporting adverse reactions.
- **Risk Evaluation and Mitigation Strategies (REMS)**: The FDA is empowered to require **REMS** for drugs that pose significant risks, such as potential life-threatening side effects. REMS may include risk communications, restricted distribution, and additional monitoring for patients using the medication.
- **Post-Marketing Surveillance**: The FDA oversees post-marketing surveillance, often conducting studies to assess drug safety long after approval. This includes monitoring the effectiveness of the REMS programs and investigating emerging safety signals. The FDA also employs **Phase IV clinical trials** to further evaluate drugs in real-world settings.
- **Drug Safety Communications**: The FDA issues public safety alerts, labeling changes, and advisories to inform healthcare professionals and patients about newly identified risks related to drugs.

Post-Marketing Surveillance: Requirements and Processes

Post-marketing surveillance (PMS) is a key component of pharmacovigilance that ensures the ongoing safety of drugs once they are released to the market. Regulatory agencies, such as the FDA and EMA, require pharmaceutical companies to monitor the safety of their products continuously and report any new safety concerns.

Requirements for Post-Marketing Surveillance

The regulatory requirements for post-marketing surveillance are designed to identify risks that may not have been apparent during pre-marketing clinical trials, especially those related to long-term use or rare adverse events.

- **Ongoing Risk Assessment**: Pharmaceutical companies are required to continuously assess the risk-benefit profile of a drug after it has been marketed. This includes reviewing adverse event reports, conducting additional clinical studies (Phase IV trials), and updating safety information as needed.
- **Spontaneous Reporting**: Both healthcare professionals and patients play a vital role in post-marketing surveillance. Spontaneous ADR reporting systems, supported by regulatory bodies, are essential for detecting potential safety issues early.
- **Periodic Safety Update Reports (PSURs)**: As part of post-marketing surveillance, pharmaceutical companies must submit **PSURs** to regulatory agencies at regular intervals. These reports provide an ongoing assessment of the drug's safety profile and highlight any newly identified risks or trends.

Challenges and Future Directions in Pharmacovigilance

Pharmacovigilance plays a pivotal role in ensuring drug safety, protecting public health, and optimizing the therapeutic benefit of medications. Despite considerable progress in global pharmacovigilance practices, there are still numerous challenges that need to be addressed for the system to function more efficiently and effectively. At the same time, advances in technology, such as artificial intelligence (AI), big data, and machine learning (ML), are transforming how pharmacovigilance systems function and hold promise for addressing many of these challenges. This chapter will explore the challenges faced by global pharmacovigilance, the technological innovations that are shaping the future of drug safety monitoring, and the potential directions in which pharmacovigilance is evolving worldwide.

While pharmacovigilance systems are essential for identifying, evaluating, and managing risks associated with pharmaceutical products, several challenges continue to hinder the effectiveness and timeliness of pharmacovigilance efforts. One of the fundamental challenges in pharmacovigilance is the quality of the data being reported. The accuracy, completeness, and timeliness of adverse event reports directly impact the ability of regulatory bodies, healthcare providers, and pharmaceutical companies to identify safety signals. Issues such as incomplete reports, lack of patient demographics, or insufficient clinical details can make it difficult to assess the true risk of a drug.

- **Inconsistent Reporting**: Global pharmacovigilance systems rely on voluntary adverse event reporting from healthcare

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2808-2814 www.ijprajournal.com ISSN: 2456-4494

professionals, patients, and pharmaceutical companies. This system can lead to underreporting, incomplete data, or inconsistent information. In some countries, the lack of awareness or reluctance to report adverse events may further exacerbate the situation.

II. CONCLUSION:

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has played a pivotal role in establishing a robust and harmonized framework for pharmacovigilance globally. As the global landscape of drug safety evolves, the ICH guidelines, particularly those related to pharmacovigilance, provide essential guidance that ensures consistency, safety, and the protection of public health worldwide. These guidelines focus on establishing uniform standards for monitoring, assessing, and managing the risks associated with pharmaceutical products, not only during the pre-marketing phase but also post-marketing.TheICH E2E (End-to-End) andE2E(R2) guidelines, along with the core principles they embody, represent a strategic approach to pharmacovigilance that incorporates risk management, signal detection, and reporting of adverse drug reactions (ADRs). These guidelines emphasize the importance of robust pharmacovigilance systems, including clear processes for the collection and reporting of ADRs, and the need for effective communication between pharmaceutical companies, regulatory bodies, and healthcare professionals. They have shaped the global pharmacovigilance landscape by ensuring that pharmacovigilance practices are consistent, standardized, and scientifically sound across different regions, promoting the safe use of medicines worldwide.WHOandICH**,** to ensure that regulatory practices are aligned and effective in safeguarding patient safety. Moving from reactive to proactive pharmacovigilance, enhanced by technological tools and harmonized global practices, holds immense promise for improving the safety of pharmaceutical products and protecting public health across the world.

REFERENCE

[1]. **World Health Organization (WHO)**. (2002). "Pharmacovigilance: A Global Responsibility." WHO Technical Report Series, 929.

[2]. **International Conference on Harmonisation (ICH)**. (1997). "E2E Pharmacovigilance: Clinical Safety Data Management." ICH Steering Committee.

[3]. **European Medicines Agency (EMA)**. (2017). "Pharmacovigilance Guidelines." European Medicines Agency.

[4]. **Food and Drug Administration (FDA)**. (2019). "FDA's Role in Pharmacovigilance." FDA Guidance Document.

[5]. **Lunde, E. A., & Solberg, E. A.** (2018). "Pharmacovigilance in Public Health: Global Approaches and Standards." Pharmacology & Therapeutics, 59(1), 42-56.

[6]. **Edwards, I. R., & Aronson, J. K.** (2000). "Adverse Drug Reactions: Definitions, Diagnosis, and Management." Lancet, 356(9237), 1255-1259.

[7]. **The International Council for Harmonisation (ICH)**. (2001). "E2E Pharmacovigilance Guideline." ICH Steering Committee.

[8]. **Miller, A. D., & Fitzsimmons, M.** (2019). "The Role of Pharmacovigilance in Ensuring Drug Safety." Journal of Drug Safety, 18(3), 299-310.

[9]. **Linden, S. L., & Fenton, E.** (2018). "A Global Overview of Pharmacovigilance and Safety Signal Detection." Drug Safety Perspectives, 24(5), 23-31.

[10]. **Begaud, B., &Pariente, A.** (2007). "Pharmacovigilance: A Comprehensive Overview." Clinical Pharmacology and Therapeutics, 81(5), 761-764.

[11]. **Stricker, B. H. C., &Mazzaglia, G.** (2017). "Global Pharmacovigilance Standards: An Overview." Pharmaceutical Policy and Law, 19(3), 145-157.

[12]. **International Society of Pharmacovigilance (ISoP)**. (2015). "Pharmacovigilance: Challenges and Advances." ISoP Annual Conference Proceedings.

[13]. **Zhou, S., & Zhao, Q.** (2019). "Signal Detection in Pharmacovigilance: From Theory to Practice." Drug Safety Journal, 27(9), 251-261.

[14]. **Davis, A., &Salama, H.** (2016). "Global Regulatory Requirements and Their Impact on Pharmacovigilance Practices." International Journal of Clinical Pharmacology, 35(7), 1023-1031.

[15]. **World Health Organization (WHO)**. (2003). "VigiBase: A Global Database for Drug Safety Surveillance." Drug Safety, 29(2), 125-133.
[16]. **Teschke, R., &Hering, N.** (2020). "Data Quality in Pharmacovigilance and Its Global Implications." Journal of Pharmacoepidemiology, 32(1), 45-58.
[17]. **Patel, R., & Srivastava, P.** (2017). "The Role of Artificial Intelligence in Pharmacovigilance." Pharmaceutical Technology, 22(4), 64-70.
[18]. **O'Neill, C. K., & Wylie, K.** (2015). "Adverse Event Reporting Systems in Pharmacovigilance: Global Systems and Emerging Trends." Regulatory Affairs Journal, 19(2), 223-237.
[19]. **Bodenreider, O., &Fiszman, M.** (2019). "Advancing Pharmacovigilance with Natural Language Processing: A Survey of Current Practices." Pharmaceutical Informatics, 22(6), 1104-1111.
[20]. **Sanchez, D., & Blake, P.** (2018). "Post-Market Surveillance and Pharmacovigilance: A Global Overview." Journal of Public Health Policy, 39(3), 384-390.
[21]. **Gelfand, R., & Huang, S.** (2020). "The Evolving Landscape of Post-Market Drug Safety Surveillance." International Journal of Risk Management, 32(7), 234-242.
[22]. **Hauben, M., & Jain, A.** (2019). "Risk Management in Pharmacovigilance: A Global Perspective." Drug Safety Monitoring, 18(5), 501-515.
[23]. **Bergman, U., &Vinnars, B.** (2016). "Global Harmonization of Pharmacovigilance and Drug Safety Regulations." Pharmaceutical Regulatory Affairs, 23(2), 215-226.
[24]. **Tomioka, S., & Ito, T.** (2020). "Enhancing Post-Marketing Surveillance through AI Technologies." Global Drug Safety Insights, 24(8), 73-85.
[25]. **ISO 9001**. (2015). "International Standards for Pharmacovigilance Data Quality." International Organization for Standardization.
[26]. **Baldwin, M., & Webster, L.** (2020). "Pharmacovigilance and the Future of Patient Safety." Global Health Policy Review, 12(4), 145-153.
[27]. **Chen, D., & Zhou, H.** (2017). "Pharmacovigilance and Global Safety Standards." Regulatory Toxicology and Pharmacology, 87(3), 225-231.
[28]. **Aymen, N., &Babah, A.** (2018). "Post-Market Safety and Global Pharmacovigilance Practices." Journal of Drug Safety Monitoring, 11(1), 20-34.
[29]. **Eichler, H. G., &Bloechl-Daum, B.** (2019). "Accelerating Drug Safety Assessments with Big Data." Journal of Pharmaceutical Medicine, 32(2), 89-94.